Abstract:Rationale & objective: Optimal approaches to treat secondary hyperparathyroidism (SHPT) in patients on maintenance hemodialysis (HD) have yet to be established in randomized controlled trials (RCTs). Study design: Two observational clinical trial emulations. Setting & participants: Both emulations included adults receiving in-center HD from a national dialysis organization. The patients who had SHPT in the period between 2009 and 2014, were insured for≥180 days by Medicare as primary payer, and did not have contraindications or poor health status limiting theoretical trial participation. Exposure: The parathyroid hormone (PTH) Target Trial emulation included patients with new-onset SHPT (first PTH 300-600pg/mL), with 2 arms defined as up-titration of either vitamin D sterols or cinacalcet within 30 days (lower target) or no up-titration (higher target). The Agent Trial emulation included patients with a PTH≥300 pg/mL while on≥6μg weekly of vitamin D sterol (paricalcitol equivalent dose) and no prior history of cinacalcet. The 2 arms were defined by the first dose or agent change within 30 days (vitamin D-favoring [vitamin-D was up-titrated] vs cinacalcet-favoring [cinacalcet was added] vs nondefined [neither applies]). Multiple trials per patient were allowed in trial 2. Outcome: The primary outcome was all-cause death over 24 months; secondary outcomes included cardiovascular (CV) hospitalization or the composite of CV hospitalization or death. Analytical approach: Pooled logistic regression. Results: There were 1,152 patients in the PTH Target Trial (635 lower target and 517 higher target). There were 2,726 unique patients with 6,727 patient trials in the Agent Trial (6,268 vitamin D-favoring trials and 459 cinacalcet-favoring trials). The lower PTH target approach was associated with reduced adjusted hazard of death (HR, 0.71 [95% CI, 0.52-0.93]), CV hospitalization (HR, 0.78 [95% CI, 0.63-0.98]), and their composite (HR, 0.74 [95% CI, 0.61-0.89]). The cinacalcet-favoring approach demonstrated lower adjusted hazard of death compared to the vitamin D-favoring approach (HR, 0.79 [95% CI, 0.62-0.99]), but not of CV hospitalization or the composite outcome. Limitations: Potential for residual confounding; low use of cinacalcet with low power. Conclusions: SHPT management that is focused on lower PTH targets may lower mortality and CV disease in patients receiving HD. These findings should be confirmed in a pragmatic randomized trial. Plain-language summary: Optimal approaches to treat secondary hyperparathyroidism (SHPT) have not been established in randomized controlled trials. Data from a national dialysis organization was used to identify patients with SHPT in whom escalated treatment may be indicated. The approach to treatment was defined based on observed upward titration of SHPT-controlling medications: earlier titration (lower target) versus delayed titration (higher target); and the choice of medication (cinacalcet vs vitamin D sterols). In the first trial emulation, we estimated a 29% lower rate of death and 26% lower rate of cardiovascular disease or death for patients managed with a lower versus higher target approach. Cinacalcet versus vitamin D-favoring approaches were not consistently associated with outcomes in the second trial emulation. This observational study suggests the need for additional clinical trials of SHPT treatment intensity.

Drugs combined with nursing intervention measures for prevention and treatment of maintenance hemodialysis clinical observation of secondary hyperparathyroidism patients

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study

Clinical Research of Hemodialysis Combined with Colon Dialysis in Uremic Patients with Hyperphosphatemia

Analysis the calcium and phosphorus metabolism disorders in Beijing chronic maintenance hemodialysis patients

Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study

The relationship between serum ceruloplasmin,calcium and phosphorus metabolism and secondary hyperprarathyroidism in hemodialysis patients

Serum calcium, phosphate, and iPTH levels of dialysis patients in Zhejiang Province

Plasma Metabolite Biomarkers Related to Secondary Hyperparathyroidism and Parathyroid Hormone.

Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia

Effect of Oral Pulse Versus Daily Alfacalcidol Therapy on Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients:A Randomized, Controlled, Multi- Center Study

Effect of Parathyroidectomy on Blood Pressure Variability in Dialysis Patients with Secondary Hyperparathyroidism

The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis

[Study of Calcium-Phosphorous Metabolism and Intact Parathyroid Hormone Levels in End Stage Renal Disease Patients].

Secondary Hyperparathyroidism in Chronic Kidney Disease: A Narrative Review Focus on Therapeutic Strategy

Effects of lanthanum carbonate on serum phosphorus in maintenance hemodialysis patients receiving calcitriol pulse therapy due to secondary hyperparathyroidism

Efficacy and Initial Dose Determination of Paricalcitol for Treatment of Secondary Hyperparathyroidism in Chinese Subjects

Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation

The Influence Upon the Levels of Serum Calcium and Parathyroid Hormone by Adjusting Dialysate Calcium Concentration in Hemodialysis Patients

Analysis of clinical efficacy of comprehensive nursing intervention on elderly patients with hypertension combined with hyperuricemia